Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10469608 | 0.84 | ACHE (0.32) | — | |
| SCHEMBL6593415 | 0.82 | — | — | |
| SCHEMBL17374771 | 0.82 | ALOX5 (0.35) | FFAR1 | |
| SCHEMBL1706476 | 0.81 | CHRM1 (0.41) | MAPT | |
| Hydrochloric Acid SCHEMBL11748281 | 0.79 | CHRM1 (0.39) | MAPT | |
| SCHEMBL29243185 | 0.78 | CES2 (0.38) | — | |
| SCHEMBL3626252 | 0.78 | CA1 (0.31) | — | |
| SCHEMBL3367883 | 0.78 | MAPT (0.44) | MAPTFFAR1 | |
| SCHEMBL6063729 | 0.78 | TET2 (0.31) | — | |
| Bicarbonate SCHEMBL29090084 | 0.77 | MAPT (0.32) | MAPTFFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737477-A2 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | Protagonist Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4706671-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250360187-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4025592-B1 | CONJUGATED HEPCIDIN MIMETICS FOR USE IN TREATING OF POLYCYTHEMIA VERA | PROTAGONIST THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4501952-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2014165449-A1 | NOVEL α4β7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140294901-A1 | NOVEL A4B7 PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140294902-A1 | NOVEL A4B7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140193465-A1 | NOVEL a4B7 PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014059213-A1 | NOVEL α4ß7 PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014047370-A1 | FLUOROALKYL DIBENZODIAZEPINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| CN-102695503-A | Halogenated aliphatic carboxylic acids, oligomers and/or polymers thereof and their use for inactivating external and internal neoplasias | MARDI MEDICINES LTD | 2012-09-26 | — | — | CN | disclosed |
| EP-2440198-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | Mardi Medicines Ltd. (IL) | 2012-04-18 | — | — | EP | disclosed |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2011-03-03 | — | — | US | disclosed |
| WO-2010143188-A2 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | MARDI MEDICINES LTD. (IL) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361280-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | MAPT 4660/4885FFAR1 3099/4885FFAR3 2762/4885 |
| US-20140193465-A1 | NOVEL a4B7 PEPTIDE DIMER ANTAGONISTS | EPCAM, ITGB7, CD2BP2 | MAPT 2958/4885FFAR1 3415/4885FFAR3 3489/4885 |
| US-20250360187-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | HAMP, HBG1, HBG2 | MAPT 4844/4885FFAR1 4165/4885FFAR3 4273/4885 |
| US-20140294902-A1 | NOVEL A4B7 PEPTIDE ANTAGONISTS | EPCAM, ITGB7, VCAM1 | MAPT 3467/4885FFAR1 3314/4885FFAR3 3092/4885 |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ANXA7, GRB7 | MAPT 2503/4885FFAR1 2602/4885FFAR3 2618/4885 |
| US-20110052641-A1 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS | CCR10, PBK, CCR3 | MAPT 3567/4885FFAR1 156/4885FFAR3 131/4885 |
| US-20140294901-A1 | NOVEL A4B7 PEPTIDE DIMER ANTAGONISTS | EPCAM, ITGB7, CD2BP2 | MAPT 2958/4885FFAR1 3415/4885FFAR3 3489/4885 |
| US-20240226225-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | MAPT 3675/4885FFAR1 3149/4885FFAR3 3505/4885 |
| US-20240209053-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, SLC40A1, FTH1 | MAPT 3901/4885FFAR1 3569/4885FFAR3 3712/4885 |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | MAPT 4776/4885FFAR1 3012/4885FFAR3 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.